ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Roche’s Genentech unit will spend $725 million to buy Seragon Pharmaceuticals, a privately held biotech firm in San Diego. Founded in 2013, Seragon is developing selective estrogen receptor degraders (SERDs) for treating hormone receptor-positive cancers. Genentech will get Seragon’s collection of small-molecule SERDs, including one targeting breast cancer that is in Phase I development. Genentech could pay up to $1 billion more should Seragon’s candidates hit certain milestones.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X